The association between thrombocytosis and subtype of lung cancer: a systematic review and meta-analysis.
The association between thrombocytosis and subtype of lung cancer: a systematic review and meta-analysis.
复制标题
血小板增多与肺癌亚型关系的系统评价和荟萃分析。
DOI：
10.21037/tcr-20-3287
复制
发表时间：
2021-03
影响因子：
0.9
通讯作者：
Bailey SER
中科院分区：
文献类型：
--
作者：
Barlow M;Hamilton W;Ukoumunne OC;Bailey SER
血小板增多症与肺癌预后不良有关，最近被认为在肺癌检测中具有很高的阳性预测价值。肺癌有多种组织学和遗传亚型，目前尚不清楚这些亚型之间的血小板水平是否存在差异，或者血小板增多是否预示着特定的亚型。PubMed和Embase使用预先指定的搜索策略，系统地搜索报告了治疗前血小板计数按肺癌亚型的平均血小板计数或患有血小板增多患者的比例的研究。采用纽卡斯尔-奥托瓦量表评估研究质量和偏倚风险。在Meta分析和亚组分析中综合了合适的研究，以检查不同亚型之间的差异。所有肺癌患者治疗前血小板增多症的患病率为27%(95%可信区间：17%至37%)。按亚型分类，腺癌为22%(95%CI：7%~41%)，鳞癌为28%(95%CI：15%~43%)，大细胞癌(LCC)为36%(95%CI：13%~62%)，小细胞肺癌(SCLC)为30%(95%CI：8%~58%)。肺癌患者合并平均血小板计数为289×109/L(95%CI：268~311)。按亚型分类，腺癌为282×109/L(95%CI：259~306)，鳞癌为297×109/L(95%CI：238~356)，肺癌为290×109/L(95%CI：176~404)，小细胞肺癌为293×109/L(95%CI：244~342)。在不同亚型中，血小板增多症的患病率(P=0.76)或平均血小板计数(P=0.96)没有差异。这些发现表明，血小板增多症并不能说明肺癌亚型中的一种优于另一种。因此，我们得出结论，高血小板计数可能在所有肺癌亚型中都是普遍存在的。
Thrombocytosis is associated with poor lung cancer prognosis and has recently been identified as having a high positive predictive value in lung cancer detection. Lung cancer has multiple histological and genetic subtypes and it is not known whether platelet levels differ across these subtypes, or whether thrombocytosis is predictive of a particular subtype. PubMed and Embase were systematically searched for studies that reported pre-treatment platelet count, as either averages or proportion of patients with thrombocytosis, by subtype of lung cancer using a pre-specified search strategy. The Newcastle-Ottowa scale was used to assess study quality and risk of bias. Suitable studies were synthesised in meta-analyses and subgroup analyses examined for differences across subtypes. The prevalence of pre-treatment thrombocytosis across all lung cancer patients was 27% (95% CI: 17% to 37%). By subtype, this was 22% (95% CI: 7% to 41%) for adenocarcinoma, 28% (95% CI: 15% to 43%) for squamous cell carcinoma (SCC), 36% (95% CI: 13% to 62%) for large cell carcinoma (LCC), and 30% (95% CI: 8% to 58%) for small cell lung cancer (SCLC). The pooled mean platelet count for lung cancer patients was 289×109/L (95% CI: 268 to 311). By subtype, this was 282×109/L (95% CI: 259 to 306) for adenocarcinoma, 297×109/L (95% CI: 238 to 356) for SCC, 290×109/L (95% CI: 176 to 404) for LCC, and 293×109/L (95% CI: 244 to 342) for SCLC. There was no difference in thrombocytosis prevalence (P=0.76) or mean platelet count (P=0.96) across the subtypes. These findings suggest thrombocytosis is no more indicative of one lung cancer subtype over another. We therefore conclude a high platelet count is likely to be generic across all lung cancer subtypes.
登录
查看更多内容
影响因子：
3.6
作者：
Farooqi AA;Siddik ZH
通讯作者：
Siddik ZH
影响因子：
45.3
作者：
Michael, M;Babic, B;Shepherd, FA
通讯作者：
Shepherd, FA
DOI：
10.3779/j.issn.1009-3419.2014.11.04
发表时间：
2014-11-01
期刊：
Zhongguo fei ai za zhi = Chinese journal of lung cancer
影响因子：
--
作者：
Li, Yanhua;Wei, Suju;Wang, Cai
通讯作者：
Wang, Cai
影响因子：
4
作者：
Li SQ;Jiang YH;Lin J;Zhang J;Sun F;Gao QF;Zhang L;Chen QG;Wang XZ;Ying HQ
通讯作者：
Ying HQ
影响因子：
5.9
作者：
Bailey, Sarah E. R.;Ukoumunne, Obioha C.;Hamilton, Willie
通讯作者：
Hamilton, Willie